How Exciting Instruments went from university spinout to first instrument on a customer's bench in 13 months | Tim Craggs

Exciting Instruments bootstrapped a physical instrument company, closed its first two sales before a working product existed, and delivered its first unit to a customer's bench 13 months after founding. Spun out of the University of Sheffield in September 2021, the company compresses what once required a laser-safe room into a benchtop any scientist can operate. In this episode of BUILDERS, we sat down with Tim Craggs, CEO and Founder of Exciting Instruments, on how he built a commercial engine from scratch, mapped three distinct customer archetypes before he had a sales team, and is now executing a deliberate pivot from academia into biotech and pharma.Topics Discussed:Bootstrapping a hard tech company through personal debt and pre-salesThree academic ICPs — and why each required a different purchase rationaleWhy 3,500 hyper-targeted followers outperformed mass reachGrant money vs. company money: how budget source changes the sales motionHow the biopharma pivot forced a product rethink: research tool to targeted assaysWhy a scientific writer is a core GTM hire in technical marketsRob's warning: "There are enough ideas to kill a company here"GTM Lessons For B2B Founders:How Exciting Instruments closed sales on physics, not product. Before the finished instrument existed, Tim used a prototype — still on an optics table in a dark room — to prove the underlying science produced usable data. The early customers weren't betting on the engineering; they were betting on the physics.How Exciting Instruments mapped three buying triggers before it had a sales team. Three distinct academic ICPs: scientists who previously had to build their own single-molecule rigs; scientists who had to collaborate with single-molecule labs and can now own the capability; and scientists who didn't know this class of experiment was possible. Three buyers, three entirely different conversations.How Exciting Instruments built a referral engine through customers, not marketing. Edwin Antony at St. Louis has brought in three to four additional customers through conference talks and word of mouth. That initial sale came partly from a tweet to Tim's 3,500-person following — hyper-targeted, not mass. When Sci Twitter fragmented, Tim tracked where it migrated and shifted his evangelism to LinkedIn.How Exciting Instruments changed its GTM motion — not just its pitch — moving into pharma. Academic buyers spend grant money; they need to believe the capability is real. Pharma buyers spend company money and justify the purchase against an existing suite of biophysical tools. For pharma, Exciting Instruments built specific assays for specific use cases: PROTAC ternary complexes, antibody aggregation, membrane protein analysis — each with its own targeted campaign.How Exciting Instruments made a scientific writer a core commercial hire. The role: translate expert-level science into language accessible to all biologists. In markets where buyer fluency varies radically across segments, translation is a conversion function.How Exciting Instruments avoided being killed by its own ideas. Rob's line: "There are enough ideas to kill a company here." The response: identify the key inflection points, align the team, and drive at those without distraction.// Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.ioThe Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co//Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM